Emergent BioSolutions Inc. (EBS) stock
EBSNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/3072% below fair value
$5.89−0.15 (-2.48%)
Close on Nov 12, 2026Market cap $302.00MP/E –Yield –
Emergent BioSolutions enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Emergent BioSolutions's enterprise value was $751.95M on Nov 11, 2026, against $1.01B a year earlier. Over the last 5 years it ranged from $751.95M to $2.96B, with a median of $1.06B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $751.95M | -29.7% |
| 2025 | Dec 31, 2025 | $1.07B | +3.8% |
| 2024 | Dec 31, 2024 | $1.03B | +14.6% |
| 2023 | Dec 29, 2023 | $898.32M | -35.9% |
| 2022 | Dec 30, 2022 | $1.40B | -49.6% |
| 2021 | Dec 31, 2021 | $2.78B | -46.7% |
| 2020 | Dec 31, 2020 | $5.21B | +50.3% |
| 2019 | Dec 31, 2019 | $3.47B | +31.0% |
| 2018 | Dec 31, 2018 | $2.65B | +44.6% |
| 2017 | Dec 29, 2017 | $1.83B | +43.2% |
| 2016 | Dec 30, 2016 | $1.28B | -14.8% |
| 2015 | Dec 31, 2015 | $1.50B | +45.5% |
| 2014 | Dec 31, 2014 | $1.03B | +43.0% |
| 2013 | Dec 31, 2013 | $721.21M | +49.0% |
| 2012 | Dec 31, 2012 | $483.90M | -9.1% |
| 2011 | Dec 30, 2011 | $532.19M | -15.9% |
| 2010 | Dec 31, 2010 | $633.14M | – |
See a number that looks wrong?